Q1 EPS Forecast for Eton Pharmaceuticals Raised by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Research analysts at B. Riley lifted their Q1 2025 EPS estimates for shares of Eton Pharmaceuticals in a report issued on Sunday, April 27th. B. Riley analyst M. El-Saadi now forecasts that the company will earn $0.13 per share for the quarter, up from their prior estimate of $0.06. B. Riley has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.64 EPS, FY2026 earnings at $1.48 EPS, FY2027 earnings at $1.86 EPS, FY2028 earnings at $2.23 EPS and FY2029 earnings at $2.46 EPS.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The business had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million.

A number of other equities analysts also recently commented on ETON. Craig Hallum lifted their target price on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Stock Down 2.6 %

NASDAQ:ETON traded down $0.46 during trading hours on Wednesday, reaching $16.89. 76,579 shares of the stock were exchanged, compared to its average volume of 180,788. Eton Pharmaceuticals has a 52 week low of $3.18 and a 52 week high of $18.41. The stock has a market capitalization of $452.82 million, a P/E ratio of -76.80 and a beta of 1.22. The firm has a 50 day simple moving average of $14.28 and a 200-day simple moving average of $13.32.

Institutional Trading of Eton Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Baader Bank Aktiengesellschaft acquired a new stake in Eton Pharmaceuticals in the 4th quarter valued at about $373,000. Jane Street Group LLC acquired a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at $90,000. Geode Capital Management LLC increased its stake in Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock worth $1,637,000 after purchasing an additional 32,365 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth about $147,000. Finally, Anchor Capital Advisors LLC purchased a new stake in Eton Pharmaceuticals during the fourth quarter valued at about $805,000. Institutional investors and hedge funds own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.